PerkinElmer, Inc. Announces First Commercial Availability Of Newborn Screening Test For Severe Combined Immunodeficiency (SCID) In U.S. and Canada

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, today announced the first commercially available screening test in the United States and Canada for Severe Combined Immunodeficiency (SCID), also known more commonly as “Bubble Boy” disease. PerkinElmer has received market authorization from the FDA and from Health Canada to offer the VICTOR™ EnLite™ and EnLite™ Neonatal TREC Kit.

Help employers find you! Check out all the jobs and post your resume.